US Patent 11053498 Compounds and methods for reducing Tau expression
Patent 11053498 was granted and assigned to Biogen on July, 2021 by the United States Patent and Trademark Office.
All edits
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.
US Patent 11053498 Compounds and methods for reducing Tau expression
Find more entities like US Patent 11053498 Compounds and methods for reducing Tau expression
